• Obsidian Therapeutics appointed Mark Reisenauer to its board of directors in November 2026.
• Reisenauer most recently served as CEO and a director of Assertio, which was acquired by Zydus Lifesciences.
• Previously president of U.S. Commercial at Astellas Pharmaceuticals, he brings more than 30 years of oncology commercialization experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Obsidian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112501893) on November 12, 2026, and is solely responsible for the information contained therein.